title: Leuconostoc as a Cause of Endophthalmitis Post-intravitreal Injection of Ranibizumab.
abstract: OBJECTIVE
  The authors report a case of endophthalmitis after intravitreal injection of ranibizumab.
  
  
  METHODS
  After searching for extensive laboratory tests to isolate the etiologic agent Results: The agent was determined as Leuconostoc mesenteroides, gram-positive cocci, vancomycin resistant.
  
  
  CONCLUSIONS
  Considerations regarding this bacterium were done by calling attention to its rarity, difficulty of isolation, and action on secondary comorbidities as opportunistic pathogen.
authors.affiliation: a Hospital Naval Marcilio Dias , Rio de Janeiro , Brazil and.
authors.forename: Nadyr P
authors.initials: NP
authors.lastname: Damasceno
authors.affiliation: a Hospital Naval Marcilio Dias , Rio de Janeiro , Brazil and.
authors.forename: Soraya A
authors.initials: SA
authors.lastname: Horowitz
authors.affiliation: b Department of Ophthalmology School of Medicine - Universidade Federal Fluminense , Niteroi , Brazil.
authors.forename: Eduardo F
authors.initials: EF
authors.lastname: Damasceno
mesh_terms: D000369:Aged, 80 and over; D000583:Amikacin / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D009877:Endophthalmitis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D015818:Eye Infections, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D016908:Gram-Positive Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D058449:Intravitreal Injections; D007934:Leuconostoc / Q000302:isolation & purification*; D008297:Male; D011183:Postoperative Complications; D000069579:Ranibizumab / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body / Q000382:microbiology; D057135:Wet Macular Degeneration / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000583:Amikacin; D000069579:Ranibizumab
keywords: Complications; Leuconostocaceae; endophthalmitis; intravitreal injections; opportunistic pathogens; ranibizumab